NasdaqGS:NBIXBiotechs
CRENESSITY Phase 3 Data on Lower Steroid Doses Could Be A Game Changer For Neurocrine Biosciences (NBIX)
Earlier this month, Neurocrine Biosciences reported new two-year Phase 3 CAHtalyst Adult data showing CRENESSITY enabled sustained reductions in glucocorticoid doses for adults with classic congenital adrenal hyperplasia, with about 70% of patients reaching physiologic dosing and no new safety concerns.
The results highlight CRENESSITY’s potential to ease long-term treatment burden by lowering reliance on supraphysiologic steroid doses while maintaining androgen control, a key clinical goal...